CAMBRIDGE, Mass., July 29, 2024 ~ Akebia Therapeutics®, Inc. (Nasdaq: AKBA) has recently announced their participation in two upcoming investor conferences in August. The biopharmaceutical company, dedicated to improving the lives of those affected by kidney disease, will be attending the BTIG virtual Biotechnology Conference on August 5-6, 2024 and the Canaccord Genuity (CG) 44th Annual Growth Conference on August 13-14, 2024 in Boston.

At the BTIG Biotechnology Conference, Akebia's Chief Executive Officer, John Butler, will be taking part in a fireside chat on Tuesday, August 6 at 8:00 am EST. Additionally, Mr. Butler will be presenting at the CG 44th Annual Growth Conference on Wednesday, August 14 at 8:30 am EST. For those unable to attend in person, a webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference. This is an exciting opportunity for investors to learn more about Akebia's advancements and future plans in the field of kidney disease treatment.

More on Boston Chron

• City of Boston Conducts 46th Annual Homelessness Census
• Boston: January 23, 2026 Traffic Advisory
• Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
• Boston's Newest Environmental Sensor Network is Complete
• PromptBuilder.cc Launches AI Prompt Generator Optimized For ChatGPT, Gemini, Grok & Claude

---

Show All News | Report Violation